ADMA Biologics Inc (NASDAQ:ADMA) – Equities researchers at Oppenheimer reduced their FY2021 earnings per share estimates for shares of ADMA Biologics in a note issued to investors on Thursday, August 8th. Oppenheimer analyst L. Gershell now expects that the biotechnology company will post earnings per share of $0.10 for the year, down from their previous forecast of $0.11. Oppenheimer has a “Buy” rating and a $14.00 price target on the stock. Oppenheimer also issued estimates for ADMA Biologics’ FY2022 earnings at $0.79 EPS and FY2023 earnings at $0.96 EPS.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.25) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.29) by $0.04. ADMA Biologics had a negative net margin of 323.54% and a negative return on equity of 273.18%. The firm had revenue of $6.56 million during the quarter, compared to analysts’ expectations of $4.36 million.

A number of other equities research analysts also recently weighed in on the company. Dawson James downgraded ADMA Biologics from a “buy” rating to a “neutral” rating in a report on Monday. HC Wainwright set a $13.00 target price on ADMA Biologics and gave the stock a “buy” rating in a report on Thursday, May 23rd. Finally, Jefferies Financial Group assumed coverage on ADMA Biologics in a report on Tuesday, June 4th. They set a “buy” rating and a $8.00 target price for the company. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. ADMA Biologics has a consensus rating of “Buy” and a consensus price target of $11.40.

ADMA stock opened at $3.86 on Monday. The company has a debt-to-equity ratio of 5.70, a quick ratio of 2.39 and a current ratio of 4.60. The stock’s fifty day moving average is $3.72. ADMA Biologics has a one year low of $2.08 and a one year high of $6.96. The company has a market capitalization of $218.88 million, a PE ratio of -2.66 and a beta of 2.71.

A number of hedge funds have recently bought and sold shares of the stock. BlackRock Inc. raised its stake in ADMA Biologics by 0.5% in the fourth quarter. BlackRock Inc. now owns 964,349 shares of the biotechnology company’s stock valued at $2,305,000 after purchasing an additional 4,577 shares in the last quarter. Raymond James & Associates raised its stake in ADMA Biologics by 65.2% in the fourth quarter. Raymond James & Associates now owns 26,871 shares of the biotechnology company’s stock valued at $64,000 after purchasing an additional 10,610 shares in the last quarter. Dimensional Fund Advisors LP acquired a new position in ADMA Biologics in the fourth quarter valued at about $34,000. Geode Capital Management LLC raised its stake in ADMA Biologics by 14.4% in the fourth quarter. Geode Capital Management LLC now owns 276,930 shares of the biotechnology company’s stock valued at $661,000 after purchasing an additional 34,818 shares in the last quarter. Finally, H D Vest Advisory Services raised its stake in ADMA Biologics by 35.0% in the second quarter. H D Vest Advisory Services now owns 135,050 shares of the biotechnology company’s stock valued at $523,000 after purchasing an additional 35,000 shares in the last quarter. 38.82% of the stock is owned by institutional investors and hedge funds.

In related news, major shareholder Life Sciences Maste Perceptive purchased 4,000,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 21st. The stock was acquired at an average price of $4.00 per share, with a total value of $16,000,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Biotest Divestiture Trust sold 5,813,954 shares of the business’s stock in a transaction dated Thursday, June 6th. The shares were sold at an average price of $3.75, for a total value of $21,802,327.50. Following the completion of the transaction, the insider now directly owns 4,295,580 shares of the company’s stock, valued at approximately $16,108,425. The disclosure for this sale can be found here. Insiders have bought 4,064,500 shares of company stock valued at $16,258,000 in the last three months. Insiders own 15.20% of the company’s stock.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.

See Also: Does the Step Transaction Doctrine Affect a Backdoor Roth IRA?

Earnings History and Estimates for ADMA Biologics (NASDAQ:ADMA)

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.